Carcinoma In Situ
22
3
5
11
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
18.2%
4 terminated out of 22 trials
73.3%
-13.2% vs benchmark
14%
3 trials in Phase 3/4
36%
4 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (22)
Project: Every Child for Younger Patients With Cancer
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer
Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices
Role of MRI Breast in Detection of Ductal Carcinoma in Situ
Handheld Ultrasound Device to Triage Women With a Positive Clinical Breast Examination by Trained Non-radiologists
Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer
Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus
PDT Plus Vitamin D3 for Anal Dysplasia
Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing
Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma
Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
Localization of Nonpalpable Breast Lesions
Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions